Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide

Cancer Research

Volumn 67, Issue 2, 2007, Pages 440-444

  Aghi, Manish ^a   Rabkin, Samuel D ^a   Martuza, Robert L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 207; MESSENGER RNA; ONCOLYTIC HERPES VIRUS; THROMBOSPONDIN 1; THROMBOSPONDIN 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DRUG MECHANISM; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; KERATITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION; VIRUS MUTATION; WESTERN BLOTTING;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; PEPTIDE FRAGMENTS; RNA, MESSENGER; THROMBOSPONDIN 1; THROMBOSPONDINS; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846707286     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3145     Document Type: Article

References (20)

1. Kefalides NA, Ziaie Z. Herpes simplex virus suppression of human endothelial matrix protein synthesis is independent of viral protein synthesis. Lab Invest 1986;55:328-36.
2. London FS, Brinker JM, Ziaie Z, et al. Suppression of host mRNA in human smooth muscle cells by a virion competent factor in herpes simplex virus type 1. Lab Invest 1990;62:189-95.
3. Ziaie Z, Friedman HM, Kefalides NA. Suppression of matrix protein synthesis by herpes simplex virus type 1 in human endothelial cells. Coll Relat Res 1986;6:333-49.
4. Choudhary A, Hiscott P, Hart CA, et al. Suppression of thrombospondin 1 and 2 production by herpes simplex virus 1 infection in cultured keratocytes. Mol Vis 2005;11:163-8.
5. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-22.
6. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001;75:9828-35.
7. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000:7:867-74.
8. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24:7802-16.
9. Cinatl J, Jr., Michaelis M, Driever PH, et al. Multi-mutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 2004;6:725-35.
10. Benencia F, Courreges MC, Conejo-Garcia JR, et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma Hum Gene Ther 2005;16:765-78.
11. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001;98:6396-401.
12. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
13. Yee KO, Streit M, Hawighorst T, et al. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β. Am J Pathol 2004;165:541-52.
14. Zadeh G, Koushan K, Pillo L, et al. Role of Ang1 and its interaction with VEGF-A in astrocytomas. J Neuropathol Exp Neurol 2004;63:978-89.
15. Wu JT, Kim DH, Wein LM. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull Math Biol 2004;66:605-25.
16. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
17. Sargiannidou I, Zhou J, Tuszynski GP. The role of thrombospondin-1 in tumor progression. Exp Biol Med (Maywood) 2001;226:726-33.
18. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003;22:63-71.
19. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98:12485-90.
20. Hoekstra R, de Vos FY, Eskens FA, et al. Phase 1 safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97.